Is Subclinical Cushing’s Syndrome an Entity or a Statistical Fallout from Diagnostic Testing? Consensus Surrounding the Diagnosis Is Required before Optimal Treatment Can Be Defined
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Subclinical hypercortisolism (SH) is a commonly used term to define subtle cortisol hypersecretion but in the absence of symptoms or signs specific of overt hypercortisolism (1, 2). This subtle cortisol excess has been described in up to 20% of patients with an adrenal incidentaloma. With 7% of subjects aged 70 yr harboring such tumors, SH is therefore potentially a common disease (3, 4). When groups of such patients are evaluated, increased body mass index, hypertension, glucose intolerance, hyperlipidemia, and reduced bone mineral density are reported, in keeping with deleterious effects of hypercortisolism. On this background, several studies have now evaluated the effect of laparoscopic adrenalectomy in reversing the biochemical and clinical features of SH with conflicting results (5–7). The latest retrospective study from Chiodini et al. (8) evaluated 108 patients from four hospitals in Milan referred over a 5-yr period. Forty-one of 108 patients were diagnosed as having SH, and of these, 25 underwent adrenalectomy in a nonrandomized fashion, and 16 were treated conservatively. The paper is novel in that it also presents data on the 67 patients who did not have SH, 30 of whom had surgery on grounds of unacceptable tumor size. They showed that blood pressure, weight, and fasting glucose responded greatest in the treated SH group when compared with both the untreated SH group and the treated non-SH group; conversely, weight, blood pressure, lipids, and glucose seemed to deteriorate in the nontreated SH group over a mean follow-up of 3 yr. The paper has limitations. It is not prospective or randomized and there was clearly a selection bias in that treated patients were younger and had bigger tumors. The absolute values for outcome measures do not always align with the percent numbers of subjects who had steady, increased, or decreased values from which the headline conclusions are drawn. Thus, 32% of treated SH subjects are stated to have a reduction in body weight after treatment, but the raw data show no overall change in body weight in this group (or in fact any of the other three groups after prolonged follow-up). Blood pressure and fasting glucose did fall in the treated SH group but also fell in the non-SH treated group, an interesting observation in its own right but one that suggests an adrenalectomy-induced effect that is independent of cortisol. The greatest area of concern, however, in this paper, and others of its kind, relates to the diagnosis of SH. First, there is a nomenclature issue here. If we agree that SH is more frequently associated with obesity, glucose intolerance, and reduced bone mass, how is this subclinical when these are established features of Cushing’s syndrome? As we debated when establishing Endocrine Society guidelines for the diagnosis of Cushing’s syndrome (9), the reality is that some of these patients will undoubtedly have mild Cushing’s syndrome, and the difficulty is securing a diagnosis at low levels of cortisol hypersecretion. Here, obesity and diabetes are potential confounders; activation of the hypothalamic-pituitary-adrenal axis with increased cortisol secretion is a hallmark of obesity (10), and demonstrating autonomous cortisol hypersecretion vs. increased secretion rate per se is crucial (9). Second, many patients labeled as having SH are likely to be victims of false-positive testing. No single test to diagnose Cushing’s syndrome has 100% sensitivity and specificity. Guidelines have deliberately recommended tests with high sensitivity so that a potentially lethal disease is not missed, and here, the initial use of one of three tests, urine cortisol, late-night salivary cortisol, or the 1-mg overnight dexamethasone suppression test (the formal 2-mg/d test over 48 h is a less patient-friendly alternative) is proposed (9). Two measures of urine cortisol are recommended because of the inherent variability in cortisol secretion. However, 5–10% of subjects with proven Cushing’s syndrome can have normal urine cortisol; the most sensitive test in patients with adrenal incidentaloma is the overnight 1-mg dexamethasone test (2, 9, 11), but here the tradeoff between high sensitivity and specificity is entirely dependent upon the cortisol cutoff points used to define pass or fail. Thus, a cortisol value of less than 1.8 μg/dl (50 nmol/liter) effectively excludes Cushing’s syndrome; sensitivity is high at over 95%, but the downside is that specificity is low at only 70–80%, effectively meaning that one in every four or five patients who do not suppress to this level will be normal with a false-positive test. Specificity can be increased to over 95% if the diagnostic threshold is raised to a cutoff cortisol of 5 μg/dl (140 nmol/liter), but with a compromise in sensitivity. Nevertheless, it is hoped that these guidelines will be seen as offering clarity, particularly in diagnosing SH where authors have used many divergent tests to apparently secure a diagnosis, tests tha
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
Self-citationThe clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Self-citationCawood, T. J., Hunt, P. J., O'Shea, D., Cole, D., & Soule, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0234 · Cited by 300
Toniato, A., Merante-Boschin, I., Opocher, G., Pelizzo, M. R., Schiavi, F., & Ballotta, E. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e31819a47d2 · Cited by 245
Chiodini, I., Morelli, V., Salcuni, A. S., Eller-Vainicher, C., Torlontano, M., Coletti, F., Iorio, L., Cuttitta, A., Ambrosio, A., Vicentini, L., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2387 · Cited by 191
Pecori Giraldi, F., Ambrogio, A. G., De Martin, M., Fatti, L. M., Scacchi, M., & Cavagnini, F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0596 · Cited by 121
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
“Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients
Mitchell, I. C., Auchus, R. J., Juneja, K., Chang, A. Y., Holt, S. A., Snyder, W. H., & Nwariaku, F. E. (2007) · Surgery · doi:10.1016/j.surg.2007.10.001 · Cited by 84
Subclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Cited by
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458
Self-citationDiagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas
Debono, M., Bradburn, M., Bull, M., Harrison, B., Ross, R. J., & Newell-Price, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3007 · Cited by 269
Eller-Vainicher, C., Morelli, V., Salcuni, A. S., Battista, C., Torlontano, M., Coletti, F., Iorio, L., Cairoli, E., Beck-Peccoz, P., Arosio, M., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0602 · Cited by 73
Palmieri, S., Morelli, V, Polledri, E., Fustinoni, S., Mercadante, R., Olgiati, L., Eller Vainicher, C., Cairoli, E., Zhukouskaya, V. V., Beck-Peccoz, P., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0803 · Cited by 57
Metadata
- Authors
- Stewart, P. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-06-01
- Volume
- 95
- Issue
- 6
- Pages
- 2618-2620
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2123994454
- Cited by
- 62
- References
- 10
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Subclinical Cushing’s Syndrome an Entity or a Statistical Fallout from Diagnostic Testing? Consensus Surrounding the Diagnosis Is Required before Optimal Treatment Can Be Defined. https://app.cochat.ai/papers/10.1210/jc.2010-0633
- The paper
- Stewart, P. M. (2010). Is Subclinical Cushing’s Syndrome an Entity or a Statistical Fallout from Diagnostic Testing? Consensus Surrounding the Diagnosis Is Required before Optimal Treatment Can Be Defined. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.